Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary Nicardipine for Coronary Microvascular Dysfunction Post-PCI
NCT03184155Phase 1Withdrawn
- Sponsor
- Thomas Jefferson University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nicardipine in Coronary Microvascular Dysfunction (CMD) (2 arms), sponsored by Thomas Jefferson University. Primary endpoint: Change in Index of Microcirculatory Resistance. Planned start Dec 2025; status: withdrawn.
02
Drugs
nicardipine
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT03184155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184155.